NASDAQ: CAMPCamp4 Therapeutics Corp Stock
$4.13+0.17 (+4.29%)
Updated Jun 16, 2026
CAMP Price
$4.13
Fair Value Price
-$3.12
Market Cap
$214.45M
52 Week Low
$1.31
52 Week High
$7.75
P/E
-1.75x
P/B
6.94x
P/S
64.93x
PEG
N/A
Dividend Yield
N/A
Revenue
$3.93M
Earnings
-$86.30M
Gross Margin
100%
Operating Margin
-2,193.72%
Profit Margin
-2,193.7%
Debt to Equity
2.41
Operating Cash Flow
-$26M
Beta
1.37
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CAMP Overview
CAMP4 Therapeutics Corporation, a biotechnology firm, was established in 2015 by Richard A. Young and Leonard Zon. Based in Cambridge, Massachusetts, its core focus is the identification and development of new therapeutic solutions for patients.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CAMP's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
CAMP
Ranked#173 of 462
Ranked#173 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $226.88 | A | |
| $52.10 | A | |
| $16.22 | A |
Be the first to know about important CAMP news, forecast changes, insider trades & much more!
CAMP News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CAMP scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CAMP ($4.13) is overvalued by 232.44% relative to our estimate of its Fair Value price of -$3.12 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CAMP ($4.13) is not significantly undervalued (232.44%) relative to our estimate of its Fair Value price of -$3.12 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CAMP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CAMP due diligence checks available for Premium users.
Valuation
CAMP fair value
Fair Value of CAMP stock based on Discounted Cash Flow (DCF)
Price
$4.13
Fair Value
-$3.12
Undervalued by
232.44%
CAMP ($4.13) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CAMP ($4.13) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CAMP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CAMP price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.75x
Industry
16.03x
Market
13.25x
CAMP price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
6.94x
Industry
4.86x
CAMP is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CAMP's financial health
Profit margin
Revenue
$1.3M
Net Income
-$18.3M
Profit Margin
-1,416.6%
CAMP's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
CAMP's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$105.5M
Liabilities
$74.6M
Debt to equity
2.41
CAMP's short-term assets ($102.20M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CAMP's short-term assets ($102.20M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CAMP's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$11.0M
Investing
$0.0
Financing
$57.0k
CAMP's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CAMP vs Biotech Stocks
Camp4 Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.